Ozicef-S 500mg/250mg Injection
Marketer
Skyways Healthcare Pvt Ltd
Salt Composition
Ceftriaxone (500mg) + Sulbactam (250mg)
Overview Ozicef-S 500mg/250mg Injection
Cefixime and Sulbactam 500mg/250mg injection is a dual-action antibiotic. It's indicated for treating diverse bacterial infections by inhibiting microbial growth and spread. This injection requires administration by a healthcare provider; adhere strictly to your prescribed dosage schedule. Complete the full treatment course, even with symptom improvement, as premature cessation can compromise its effectiveness. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia; consult your physician if any worsen. Seek immediate medical attention for allergic reactions (e.g., rash, itching, swelling, dyspnea). Inform your doctor of all current medications, including over-the-counter drugs, before commencing treatment. Pregnant or lactating individuals should consult their doctor prior to use. Alcohol consumption should be avoided due to potential increased drowsiness. While generally not impairing driving ability, refrain from driving if experiencing drowsiness or dizziness. Adequate rest, proper nutrition, and hydration are crucial for optimal recovery. Your doctor may order blood tests and other diagnostics to monitor treatment response.
Uses of Ozicef-S 500mg/250mg Injection
Infections caused by bacteria
Major Benefits of Ozicef-S 500mg/250mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Ozicef-S 500mg/250mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Ozicef-S 500mg/250mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Ozicef-S 500mg/250mg Injection works:
Ceftriaxone and Sulbactam, combined as Ozicef-S 500mg/250mg Injection, offer a targeted antibacterial approach. Ceftriaxone, a cephalosporin antibiotic, disrupts bacterial cell wall synthesis, hindering their growth and survival. Sulbactam, a beta-lactamase inhibitor, complements Ceftriaxone by neutralizing enzymes that bacteria use to resist antibiotic action, thereby maximizing Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
The concomitant use of alcohol and Ozicef-S 500mg/250mg Injection presents no known adverse reactions.
PregnancySAFE IF PRESCRIBED
The injectable medication Ozicef-S (500mg/250mg) is typically deemed safe for use during gestation. Preclinical trials in animals revealed minimal or no negative impacts on fetal development; nevertheless, clinical data from human trials are scarce.
Breast feedingCAUTION
The administration of Ozicef-S 500mg/250mg Injection to breastfeeding mothers requires careful consideration. Mothers should discontinue breastfeeding for the duration of treatment and until the medication is fully cleared from their system.
DrivingUNSAFE
The injection Ozicef-S, 500mg/250mg, can cause drowsiness, blurred vision, and dizziness. Refrain from driving if you experience these side effects.
KidneyCONSULT YOUR DOCTOR
Data regarding the administration of Ozicef-S 500mg/250mg Injection to individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
Patients with severe hepatic impairment should use the Ozicef-S 500mg/250mg Injection cautiously, potentially requiring a modified dosage. Medical advice is recommended. Dosage modification for Ozicef-S 500mg/250mg Injection is unnecessary for individuals with mild to moderate liver dysfunction.
What if you forget to take Ozicef-S 500mg/250mg Injection :
Omitting a scheduled dose of Ozicef-S 500mg/250mg Injection warrants immediate physician consultation.
Facts to Know About Ozicef-S 500mg/250mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-Infective Agents |
3,018 People bought this recently